tiprankstipranks
Trending News
More News >
Tandem Diabetes Care (TNDM)
NASDAQ:TNDM
Advertisement

Tandem Diabetes Care (TNDM) AI Stock Analysis

Compare
1,432 Followers

Top Page

TNDM

Tandem Diabetes Care

(NASDAQ:TNDM)

Rating:49Neutral
Price Target:
$12.00
▼(-4.08% Downside)
The overall stock score reflects significant financial performance concerns, with high leverage and negative profitability being major risks. While the earnings call and corporate events provide some positive outlook, the technical analysis and valuation indicate caution. The stock's bearish trend and negative P/E ratio suggest potential overvaluation and limited immediate upside.
Positive Factors
Growth Opportunities
Management is optimistic about the US opportunity and believes it will continue to make progress towards margin expansion and cash flow generation.
Market Dynamics
The CMS proposal could drive further adoption by increasing the number of patients interested in pump therapy and decreasing out-of-pocket costs.
Product Development
The clearance for the seven-day SteadiSet and future launch of the tubeless Mobi (Tobi) in 2026 is expected to enhance product offerings.
Negative Factors
Competitive Pressure
The company continues to face competition as it invests in the product pipeline and works towards profitability.
Growth Expectations
Management lowered new U.S. pumpers to flat-to-slightly down from up, indicating challenges in growth expectations.
Revenue Performance
Tandem missed Q2 revenue estimates, including US pump revenue, and the company’s reduced FY25 guidance reflects this.

Tandem Diabetes Care (TNDM) vs. SPDR S&P 500 ETF (SPY)

Tandem Diabetes Care Business Overview & Revenue Model

Company DescriptionTandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
How the Company Makes MoneyTandem Diabetes Care generates revenue primarily through the sale of its insulin delivery devices, including the t:slim X2 insulin pump and related accessories. The company also earns money from the sale of disposable supplies, such as infusion sets and reservoirs, which are necessary for the operation of their insulin pumps. A significant revenue stream comes from partnerships with insurance providers and healthcare organizations that facilitate access to their products for patients. Additionally, Tandem may benefit from collaborations with technology companies to enhance its product offerings and expand its market reach. The company's consistent focus on innovation and customer support helps to drive sales and build loyalty among users, further contributing to its overall earnings.

Tandem Diabetes Care Earnings Call Summary

Earnings Call Date:Aug 06, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 29, 2025
Earnings Call Sentiment Neutral
The earnings call showcased Tandem Diabetes Care's strong performance with record sales and significant progress in pharmacy channel expansion and international markets. However, there are challenges such as moderate U.S. sales growth and increased competition affecting the future outlook.
Q2-2025 Updates
Positive Updates
Record Second Quarter Sales
Tandem Diabetes Care achieved record second quarter sales, both in the U.S. and internationally, with worldwide sales of $241 million, marking the highest second quarter sales in both markets.
Strong Pump Shipments and Renewals
There was a year-over-year increase in pump shipments in the U.S., with renewals accounting for over half of the shipments, demonstrating strong retention and continued double-digit growth in renewals.
Pharmacy Channel Expansion
Progress in pharmacy channel expansion with plans to start selling t:slim supplies through the pharmacy channel beginning in Q4, aimed at making pump therapy more affordable and lowering out-of-pocket costs for patients.
International Market Growth
Strong performance in international markets with $70 million in sales, driven by demand for t:slim, increasing pump renewals, and growing supply sales.
Gross Margin Improvement
Achieved a gross margin of 52%, reflecting an increase year-over-year and compared to the first quarter, driven by pricing improvements and operational goals.
Product Development Milestones
Significant product development milestones achieved in Q2, including the Tandem Mobi's positive feedback and the upcoming integration with Abbott's FreeStyle Libre 3 Plus sensor.
Negative Updates
U.S. Sales Growth Moderation
U.S. sales anticipated to have more moderate growth in the back half of the year due to the competitive environment and ongoing commercial transformation efforts.
Impact of New Market Entrants
Acknowledgment of increased competition from a new market entrant with a large sales organization, expected to cause some market noise and pausing in the second half.
Inventory Adjustments
Slight headwinds from distributor inventory adjustments in international markets in preparation for the transition to direct operations in 2026.
Challenges in U.S. Commercial Transformation
The commercial transformation, including sales force expansion and system upgrades, is still in process, delaying some anticipated benefits.
Company Guidance
During Tandem Diabetes Care's second quarter 2025 earnings call, the company provided several key metrics and guidance for the fiscal year. Tandem reported record second-quarter sales of $241 million, marking a 15% year-over-year growth, with $170 million of sales in the U.S. and $70 million internationally. The company achieved a gross margin of 52%, with expectations to reach 53%-54% by year-end and a longer-term target of 60% by the end of 2026. Tandem is on track to achieve $1 billion in worldwide sales for 2025, with U.S. sales anticipated at $700 million and international sales at $300 million. The company highlighted the expansion of its pharmacy channel, noting that approximately 30% of U.S. lives are now covered, and new partnerships are expected to increase this coverage. Tandem also plans to start selling t:slim supplies through the pharmacy channel in Q4, which could significantly impact its financial performance. Additionally, Tandem is focusing on the type 2 diabetes market, expanding pilot programs that showed increased adoption compared to non-pilot areas. The company is also looking forward to launching new products, such as the Steadiset infusion set and the tubeless Mobi pump, both expected in 2026.

Tandem Diabetes Care Financial Statement Overview

Summary
Tandem Diabetes Care faces profitability challenges despite strong revenue growth. High leverage and negative cash flow trends pose financial risks, impacting long-term sustainability. The company must focus on sustaining margins and reducing debt for future financial health.
Income Statement
40
Negative
Tandem Diabetes Care's income statement shows a mixed performance. The TTM (Trailing-Twelve-Months) gross profit margin is healthy at 46.6%, indicating effective cost management. However, the company is struggling with profitability, as evidenced by negative net profit margin (-16.7%) and EBIT margin (-9.4%). Revenue growth is strong with a 17.2% increase from the previous year, but consistent operating losses are a concern.
Balance Sheet
35
Negative
The balance sheet reflects financial vulnerability with a high debt-to-equity ratio of 3.18, suggesting significant leverage. The equity ratio of 16.8% indicates heavy reliance on debt for financing. Return on equity is negative at -118.4%, reflecting poor returns for shareholders. The company maintains a reasonable cash position, but overall financial stability is weak.
Cash Flow
45
Neutral
Cash flow analysis reveals challenges, with negative free cash flow in the TTM period. The operating cash flow to net income ratio is 0.08, showing limited cash generation from operations. The free cash flow to net income ratio is negative, indicating cash outflows exceeding net income. Although there is a positive free cash flow growth from 2023 to 2024, the overall cash flow health is concerning.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.12B940.20M747.72M801.22M702.80M498.83M
Gross Profit526.37M489.57M367.69M412.99M376.21M260.52M
EBITDA-177.66M-99.13M-194.66M-72.31M36.50M-13.03M
Net Income-205.45M-96.03M-222.61M-94.59M15.57M-34.38M
Balance Sheet
Total Assets875.74M967.66M952.66M1.05B905.14M716.41M
Cash, Cash Equivalents and Short-Term Investments315.36M438.33M467.91M616.90M623.81M484.94M
Total Debt449.01M473.56M415.67M419.88M314.67M228.32M
Total Liabilities742.45M704.56M639.03M612.84M472.02M350.11M
Stockholders Equity133.28M263.10M313.63M439.95M433.11M366.31M
Cash Flow
Free Cash Flow-54.16M4.99M-83.41M7.51M87.85M-7.63M
Operating Cash Flow9.72M24.23M-31.81M50.46M111.36M24.67M
Investing Cash Flow52.43M-23.48M-85.74M33.17M-186.88M-296.06M
Financing Cash Flow-46.62M8.37M4.11M16.88M51.93M314.44M

Tandem Diabetes Care Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price12.51
Price Trends
50DMA
14.83
Negative
100DMA
17.44
Negative
200DMA
23.62
Negative
Market Momentum
MACD
-0.85
Negative
RSI
46.76
Neutral
STOCH
77.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNDM, the sentiment is Neutral. The current price of 12.51 is above the 20-day moving average (MA) of 11.89, below the 50-day MA of 14.83, and below the 200-day MA of 23.62, indicating a neutral trend. The MACD of -0.85 indicates Negative momentum. The RSI at 46.76 is Neutral, neither overbought nor oversold. The STOCH value of 77.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TNDM.

Tandem Diabetes Care Risk Analysis

Tandem Diabetes Care disclosed 62 risk factors in its most recent earnings report. Tandem Diabetes Care reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Tandem Diabetes Care Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
$23.93B103.4419.18%25.99%-40.46%
73
Outperform
$1.62B24.3619.29%40.98%34.80%
69
Neutral
$1.28B17.744.76%-0.61%
68
Neutral
$29.54B52.7422.83%9.30%-14.95%
61
Neutral
$3.08B30.62-17.87%8.57%-1154.64%
51
Neutral
$7.86B-0.26-41.41%2.22%22.87%-2.01%
49
Neutral
$845.29M-111.91%25.84%-47.67%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TNDM
Tandem Diabetes Care
12.51
-29.26
-70.05%
DXCM
Dexcom
75.34
2.98
4.12%
PODD
Insulet
339.88
133.19
64.44%
UFPT
Ufp Technologies
210.16
-117.15
-35.79%
LIVN
LivaNova
56.37
6.79
13.70%
AHCO
AdaptHealth
9.49
-1.39
-12.78%

Tandem Diabetes Care Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Tandem Diabetes Care Gains FDA Clearance for SteadiSet
Positive
Aug 7, 2025

On August 6, 2025, Tandem Diabetes Care received FDA clearance for its SteadiSet infusion set, designed for up to seven days of insulin delivery for type 1 diabetes patients. The company plans to launch SteadiSet as a standalone product and as part of its future Tandem Mobi tubeless system, with a focus on scaling up manufacturing and pre-commercial activities in the coming quarters.

Executive/Board ChangesLegal ProceedingsShareholder Meetings
Tandem Diabetes Care Settles Patent Disputes with Roche
Neutral
May 23, 2025

On May 21, 2025, Tandem Diabetes Care, Inc. and Roche entities settled patent disputes related to insulin delivery systems, agreeing to terminate pending actions and granting each other non-exclusive licenses for ten years. Additionally, Tandem held its virtual Annual Meeting of Stockholders on the same day, where eight directors were elected, executive compensation was approved, and Ernst & Young LLP was ratified as the independent registered public accounting firm for 2025.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 23, 2025